Hong Kong Baptist

Company snapshot

Hong Kong Baptist is a pharma organization headquartered in CN. Primary therapeutic focus areas include Eczema, GERD (Heartburn, Regurgitation, and Dyspepsia) Frequency, Infantile Colic, Feeding and Eating Disorders of Childhood, Neisseria Gonorrhoeae Infection. NovaPharmaNews links 18 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (5), phase 1 (4), phase 3 (2).

• 18 active pipeline program(s) linked via ClinicalTrials.gov.
• 18 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hong Kong Baptist. Not investment advice.

• Peer + 0 momentum

  Sanofi Pasteur MSD

  TA overlap score 36.6

• Peer + 0 momentum

  vTv Therapeutics

  TA overlap score 22.8

• Peer + 0 momentum

  Oramed Pharmaceuticals

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for Hong Kong Baptist.

1. Jun 8, 2026 Clinical update

   Prospan cough Syrup — Unknown

2. Jun 8, 2026 Clinical update

   MaZiRenWan (MZRW) — Phase 2

3. Jun 8, 2026 Clinical update

   glargine + exenatide — Approved

4. Jun 8, 2026 Clinical update

   Ceftriaxone 1000mg + doxycycline 100 mg — Phase 2

5. Jun 5, 2026 Clinical update

   BioAmicus Complete — Unknown

View all clinical trial activity →

• What is Hong Kong Baptist?

  Hong Kong Baptist is a pharma organization headquartered in CN. Primary therapeutic focus areas include Eczema, GERD (Heartburn, Regurgitation, and Dyspepsia) Frequency, Infantile Colic, Feeding and Eating Disorders of Childhood, Neisseria Gonorrhoeae Infection. NovaPharmaNews li

• Is Hong Kong Baptist publicly traded?

  Hong Kong Baptist appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Hong Kong Baptist develop or market?

  We link 14 drug profile(s) where Hong Kong Baptist is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/hong-kong-baptist-university#company-drugs.

• What are the latest developments for Hong Kong Baptist?

  In the last 12 months our linked public records show 18 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Hong Kong Baptist focus on?

  Hong Kong Baptist focuses on Eczema, GERD (Heartburn, Regurgitation, and Dyspepsia) Frequency, Infantile Colic based on our analysis of their pipeline programs and drug development activities.